Pamiparib

Pamiparib

Pamiparib

A PARP inhibitor anti-cancer drug compound

Pamiparib, sold under the brand name Partruvix, is a pharmaceutical drug used for the treatment of various types of cancer. Pamiparib is a member of the PARP inhibitor drug class.[1]

Quick Facts Clinical data, Trade names ...

In China, it is approved for the treatment of germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube, and primary peritoneal cancers previously treated with two or more lines of chemotherapy.[2]

It is currently under investigation for the treatment of other forms of cancer.[3][1]

References

  1. [1]
    Xiong Y, Guo Y, Liu Y, Wang H, Gong W, Liu Y, et al. (September 2020). "Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor". Neoplasia. 22 (9): 431–440. doi:10.1016/j.neo.2020.06.009. PMC 7350150. PMID 32652442.
  2. [2]
    Markham A (July 2021). "Pamiparib: First Approval". Drugs. 81 (11): 1343–1348. doi:10.1007/s40265-021-01552-8. PMID 34287805.
  3. [3]
    Friedlander M, Mileshkin L, Lombard J, Frentzas S, Gao B, Wilson M, et al. (September 2023). "Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial". British Journal of Cancer. 129 (5): 797–810. doi:10.1038/s41416-023-02349-0. PMC 10449784. PMID 37474720.


Stub icon

This oncology article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Pamiparib, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.